logo

For the Inventor, By the Inventor

Raichur, India

Prashant Purohit

This inventor holds 7 USPTO granted patents and 7 published patent applications. Top assignee: Shilpa Medicare Limited. Active years: 2014-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Prashant Purohit. Retrieved from https://idiyas.com/inventor/prashant-purohit

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7 

% Patents Active = 14.3

Average Co-Inventor Count = 4.5

ph-index = 2

Forward Citations = 9(Granted Patents)


Location History:

  • Vizianagaram, IN (2015)
  • Karnataka, IN (2014 - 2016)
  • Raichur, IN (2014 - 2017)

Company Filing History:

goldMedal7 out of 32 
 
Shilpa Medicare Limited
 patents

Years Active: 2014-2017

Loading Chart...
7 patents (USPTO):Explore Patents
1. 9790185 - Process for the preparation of regorafenib and its crystalline forms (2017-10-17),
2. 9593083 - Crystalline erlotinib hydrochloride process (2017-03-14),
3. 9403785 - Process for preparing amorphous cabazitaxel (2016-08-02),
4. 9266816 - Fingolimod polymorphs and their processes (2016-02-23),
5. 9145406 - Process for preparing dasatinib monohydrate (2015-09-29),
6. 8895772 - Process for preparing bicalutamide (2014-11-25),
7. 8829210 - Process for preparing docetaxel and its hydrate (2014-09-09),

Title: Prashant Purohit: Innovator in Pharmaceutical Chemistry

Introduction

Prashant Purohit is a notable inventor based in Raichur, India. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of processes for the preparation of important cancer treatment compounds. With a total of 7 patents to his name, Purohit's work is recognized for its impact on the pharmaceutical industry.

Latest Patents

Among his latest patents is a process for the preparation of regorafenib and its crystalline forms. This invention relates to a method for producing 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide, commonly known as Regorafenib. The patent also details a purification process to yield highly pure material, which is essential for pharmaceutical compositions aimed at treating cancer. Another significant patent involves the preparation of crystalline erlotinib hydrochloride, characterized by specific X-ray powder diffraction patterns and thermal properties, making it useful as an active pharmaceutical ingredient in cancer treatments.

Career Highlights

Prashant Purohit is currently associated with Shilpa Medicare Limited, a company known for its focus on developing and manufacturing high-quality pharmaceutical products. His work at Shilpa Medicare has allowed him to contribute to innovative solutions in cancer treatment, enhancing the efficacy and safety of medications available to patients.

Collaborations

Throughout his career, Purohit has collaborated with talented professionals, including Vimal Kumar Shrawat and Vinod Kumar Singh. These collaborations have fostered a productive environment for innovation and have led to the successful development of several important pharmaceutical processes.

Conclusion

Prashant Purohit's contributions to pharmaceutical chemistry exemplify the vital role of inventors in advancing medical science. His innovative processes for drug preparation not only enhance treatment options for cancer patients but also reflect the importance of collaboration in achieving significant breakthroughs in the field.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…